Syros Pharmaceuticals Inc banner

Syros Pharmaceuticals Inc
NASDAQ:SYRS

Watchlist Manager
Syros Pharmaceuticals Inc Logo
Syros Pharmaceuticals Inc
NASDAQ:SYRS
Watchlist
Price: 0.0002 USD
Market Cap: $5.4k

Relative Value

There is not enough data to reliably calculate the relative value of SYRS.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SYRS Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

SYRS Competitors Multiples
Syros Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Syros Pharmaceuticals Inc
NASDAQ:SYRS
5.4k USD 0 -0 0.2 0.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
369.9B USD 6.1 88.5 14.7 20.4
US
Amgen Inc
NASDAQ:AMGN
190B USD 5.2 24.7 14.3 14.3
US
Gilead Sciences Inc
NASDAQ:GILD
175.3B USD 6 20.7 12.9 15.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.3B USD 9.6 29.3 22 23
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD 5.5 17.6 13 14.9
AU
CSL Ltd
ASX:CSL
67.1B AUD 3.1 34.1 11.3 14.2
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
NL
argenx SE
XBRU:ARGX
36.5B EUR 10.4 33.4 36.1 36.9
P/S Multiple
Revenue Growth P/S to Growth
US
Syros Pharmaceuticals Inc
NASDAQ:SYRS
Average P/S: 3 063 002.7
0
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.1
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.2
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
6
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
11%
0.9
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
10%
0.6
AU
CSL Ltd
ASX:CSL
3.1
4%
0.8
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
NL
argenx SE
XBRU:ARGX
10.4
27%
0.4
P/E Multiple
Earnings Growth PEG
US
Syros Pharmaceuticals Inc
NASDAQ:SYRS
Average P/E: 35.5
Negative Multiple: -0
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
88.5
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.7
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
20.7
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
29.3
16%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.6
13%
1.4
AU
CSL Ltd
ASX:CSL
34.1
10%
3.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
NL
argenx SE
XBRU:ARGX
33.4
32%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Syros Pharmaceuticals Inc
NASDAQ:SYRS
Average EV/EBITDA: 15.6
0.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.7
12%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.3
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13
18%
0.7
AU
CSL Ltd
ASX:CSL
11.3
7%
1.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
NL
argenx SE
XBRU:ARGX
36.1
50%
0.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Syros Pharmaceuticals Inc
NASDAQ:SYRS
Average EV/EBIT: 17.5
0.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20.4
24%
0.8
US
Amgen Inc
NASDAQ:AMGN
14.3
3%
4.8
US
Gilead Sciences Inc
NASDAQ:GILD
15.9
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.9
23%
0.6
AU
CSL Ltd
ASX:CSL
14.2
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
NL
argenx SE
XBRU:ARGX
36.9
56%
0.7
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett